Boston Scientific
BSXWhat is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.
At $43.64 (close on November 18) and with the other assumptions at their starting point, Boston Scientific's sales would need to grow 11.1% a year for ten years; over its last decade, the median was 10.8%. Value it with your own assumptions.
Its accounts, year by year
| Year end | Sales | Growth | Margin |
|---|---|---|---|
| 12/2015 | 8,068 | — | −2.2% |
| 12/2016 | 9,076 | 12.5% | 6.2% |
| 12/2017 | 9,048 | −0.3% | 15.6% |
| 12/2018 | 9,823 | 8.6% | 16.8% |
| 12/2019 | 10,735 | 9.3% | 15.6% |
| 12/2020 | 9,913 | −7.7% | 0.9% |
| 12/2021 | 11,888 | 19.9% | 11.7% |
| 12/2022 | 12,682 | 6.7% | 14.7% |
| 12/2023 | 14,240 | 12.3% | 18.1% |
| 12/2024 | 16,747 | 17.6% | 17.1% |
| 12/2025 | 20,074 | 19.9% | 19.5% |
Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Boston Scientific files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.
The model's starting point
- Sales growth, years 1 to 10: 17.6% a year.
- Sales growth after year 10: 2.5% a year.
- Operating margin, before stock pay: 18.1% of sales.
- Working capital needed to grow: $8.7 per $100 of new sales.
- Capital spending: 4.7% of sales.
- Stock pay to employees: 4.1% of sales.
- Discount rate, the same for every company: 10%.
These are the six assumptions the page starts with; each user moves them as they see fit.
Reference points
They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.
For
- It is growing faster than before: 17.6% a year in the last three fiscal years, against 10.8% over the whole decade.
- Its margin has risen over these years, from 6% to 18%.
- Its share price moves less than the market: a five-year beta of 0.77; the median is 0.94.
- Its sales grew 9.5% a year on average over 10 years, from $8.1 billion to $20.1 billion; the median of grinboss companies is 6.6%.
Against
- Its stock pay to employees comes to 4.1% of sales, more than the median (1.5%). That is a part of the company that stops belonging to the shareholders.
- It ties up $9 in inventory and unpaid customer bills for every $100 of new sales, more than the median ($2).
- Its margin jumps from one year to the next: 5.5 points on average, and up to 14.7 in a single year; the median is 2.8 points.
- Its net debt equals 2.1 years of operating profit plus depreciation and amortization (EBITDA), more than the median (1.5).
Next results: February 3, 2027.
Other companies in its sector (Health Care)
Cardinal Health (CAH) · Cooper Companies (COO) · Cencora (COR) · Charles River Laboratories (CRL) · CVS Health (CVS) · Quest Diagnostics (DGX) · Danaher Corporation (DHR) · DaVita (DVA) · All companies
Loading the model…